San Francisco, 26
October 2018: The global cancer supportive care drugs market size is expected to be valued at USD 23.5 billion by
2022, as per a new report by Grand View Research, Inc., progressing at a CAGR
of 1.8% during the forecast period. The market is anticipated to be driven by
large number of side-effects associated with cancer treatment, increasing
uptake of biosimilars, rising expenditure on healthcare, and availability of
effective treatment methods, including target specific and tailored treatments.
Chemotherapy and
radiotherapy are traditional methods for cancer treatment with approximately
four million people receiving chemotherapy every year. Supportive care products
are essential to prevent and manage symptoms and side-effects of cancer and its
treatment.Among major cancer types, lung and breast cancers are the most
prominent cancer type with the highest demand for supportive care drugs.
G-CSFs and ESAs
therapeutic classes are witnessing a fundamental shift from biologics to
biosimilars. The market for cancer pain, chemotherapy induced nausea and
vomiting, and cancer induced bone diseases will grow significantly during the
forecast period, due to new product launches and high unmet needs. The cancer
pain market is estimated to witness a shift from opioids to non-opioids
therapies. The shift will be backed by patent loss, high mortality, addiction,
and major safety issues associated with narcotic agents.
Access Research Report
of Cancer Supportive Care
Drugs Market @ www.grandviewresearch.com/industry-analysis/cancer-supportive-care-drugs-market
Further key findings from the report suggest:
· Some of the key players operating in this industry are
Amgen, Johnson & Johnson, Merck, Roche, Helsinn Healthcare, Heron Pharma,
and Tesaro
· Among EU5, Germany captured the second
position in the global cancer support care drugs market. Japan is poised to
witness the fastest growth over the forecast period
· The CINV drugs market will be propelled by
widening base of patients, increasing adoption of chemotherapeutic drugs, and
launch of new drug delivery approaches to improve patient compliance
· In Europe, Zarzio has taken over its
reference product Neupogen in terms of market share
· Late stage pipeline products include
non-opioids such as Tanezumab and HTX-011
· Newer immunotherapies directed against PD-1
ligands and PD-L1 proteins have shown to be more effective with a superior
safety profile
Browse more reports of this category by Grand View
Research at: www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has
segmented the global cancer supportive care drugs market based on drug class
and treatment:
Cancer Supportive Care Drugs Therapeutic Class
Outlook (Revenue, USD Million, 2016 - 2022)
o
G-CSFs
o
ESAs
o
Antiemetics
o
Bisphosphonates
o
Opioids
o
NSAIDs and others
Cancer Supportive Care Drugs Regional Outlook
(Revenue, USD Million, 2016 - 2022)
o
U.S.
o
U.K.
o
France
o
Germany
o
Italy
o
Spain
o
Japan
Access Press Release of
Cancer Supportive Care Drugs Market@ www.grandviewresearch.com/press-release/global-cancer-supportive-care-drugs-market
About
Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research
reports, and consulting services. To help clients make informed business
decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
No comments:
Post a Comment